Syntax Research Inc. Has $1.11 Million Stake in Thermo Fisher Scientific Inc. $TMO

Syntax Research Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 55.6% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,210 shares of the medical research company’s stock after selling 2,772 shares during the period. Thermo Fisher Scientific makes up 0.8% of Syntax Research Inc.’s investment portfolio, making the stock its 19th biggest holding. Syntax Research Inc.’s holdings in Thermo Fisher Scientific were worth $1,108,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. J. Stern & Co. LLP lifted its position in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. BlackRock Inc. bought a new position in Thermo Fisher Scientific in the second quarter worth $15,501,867,000. State Street Corp boosted its stake in Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Corient Private Wealth LP acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $382,547,000. Finally, Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Piper Sandler upped their price objective on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Stock Up 1.7%

NYSE:TMO opened at $618.91 on Friday. The stock’s fifty day moving average price is $568.92 and its two-hundred day moving average price is $514.41. The company has a market cap of $228.84 billion, a price-to-earnings ratio of 33.29, a P/E/G ratio of 2.54 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock worth $44,122,820 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.